10 health economics and outcomes research experts
Vertex Pharmaceuticals links four of the health economics and outcomes research careers here: Adeline Durand works there now, and Xingdi Hu, Brooke S. Harrow and Kyle Hvidsten held outcomes or health economics titles there. The rest of the group adds HEOR leads for cardiovascular at Novartis, oncology at Astellas Pharma and field HEOR at Bristol Myers Squibb, useful when planning value evidence, an economic model or an HTA submission for a new product.
Professionals to explore
Adeline Durand
LinkedInExperience: Former Director, Health Economics & Outcomes Research · Vertex Pharmaceuticals
$471 per 30-minute call
Adeline Durand, based in the United Kingdom, became Director, Health Economics & Outcomes Research at Vertex Pharmaceuticals in February 2026 after Associate Director, Health Economics & Outcomes Research there (2022–2026). Adeline was HEOR Manager at Novartis (2019–2022) and Merck Group (2018–2019) and Health Economics Advisor at Eli Lilly and Company (2016–2017), a fit for HEOR project work across several companies.
Is this you? Claim your profile and get paid for calls.
Agathe Le Lay
LinkedInExperience: Director and Head of Health Economics & Outcomes Research · Lundbeck
$471 per 30-minute call
Agathe Le Lay has been Director and Head of Health Economics & Outcomes Research at Lundbeck since November 2017 and Vice President, Head of Global Value Evidence & Patient Insights at H. Lundbeck A/S since February 2023. Agathe also held Senior Director Value Evidence (2019–2023) and Market Access Manager (2008–2010) at Lundbeck and is a Guest Lecturer at Copenhagen Business School, a fit for building a global value evidence function.
Is this you? Claim your profile and get paid for calls.
Ankur A. Dashputre
LinkedInExperience: Former Director, Health Economics and Outcomes Research · BioNTech SE
$471 per 30-minute call
Since January 2024, Ankur A. Dashputre has been Director, Health Economics and Outcomes Research at BioNTech SE, after Director, HEOR (2023–2024) and Associate Director, HEOR (2021–2023) at Bausch Health Companies Inc. Ankur has peer-reviewed publications in real world evidence using large database analytics of administrative claims and electronic medical records, health economic modeling and systematic literature reviews.
Is this you? Claim your profile and get paid for calls.
Bhavik J. Pandya
LinkedInExperience: Former Global Director, Health Economics and Outcomes Research (HEOR) Oncology · Astellas Pharma
$606 per 30-minute call
At Astellas Pharma, Bhavik J. Pandya has been Lead, Global Value Evidence Oncology, Prostate Cancer Portfolio since August 2024, developing and executing global value evidence strategies for XTANDI and pipeline assets in prostate cancer. Bhavik's earlier Astellas titles are Global Director, Health Economics and Outcomes Research (HEOR) Oncology (2022–2024), Director, US Oncology Health Economics and Outcomes Research (2016–2022) and Associate Director, HECOR Oncology (2013–2016).
Is this you? Claim your profile and get paid for calls.
Bhavini P. Srivastava
LinkedInExperience: Director, Health Economics and Outcomes Research · AbbVie
$471 per 30-minute call
Bhavini P. Srivastava has been Director, Health Economics and Outcomes Research at AbbVie since April 2022, as HEOR Strategy Lead for Imbruvica and Etentamig. Bhavini was Associate Director, Global Value and HEOR at Jazz Pharmaceuticals (2019–2022), Program Manager, Health Economics and Reimbursement at Abbott (2018–2019) and Manager, Health Economics and Outcomes Research at Pharmacyclics, an AbbVie Company (2015–2018), with budget impact, cost effectiveness and cost utility models among stated specialties.
Is this you? Claim your profile and get paid for calls.
Brooke S. Harrow
LinkedInExperience: Senior Director, Health Economics and Outcomes Research · Deciphera Pharmaceuticals
$539 per 30-minute call
Senior Director, Health Economics and Outcomes Research at Deciphera Pharmaceuticals since April 2021, Brooke S. Harrow has a record of leading successful reimbursement submissions. Brooke was Director, Global HEOR at Ipsen (2019–2021), Director, Health Economics and Outcomes Research at TESARO, Inc. (2015–2019), Senior Director and Head, Health Economics and Outcomes Research at Meda in the US (2013–2015) and Director, Health Outcomes, Global Market Access and Value at Vertex Pharmaceuticals (2011–2013).
Is this you? Claim your profile and get paid for calls.
Gabrielle Williams
LinkedInExperience: Executive Director, Field HEOR · Bristol Myers Squibb
$673 per 30-minute call
Field HEOR is Gabrielle Williams's area at Bristol Myers Squibb: Executive Director, Field HEOR since June 2026, Senior Director, Field Health Economics & Outcomes Research (2025–2026) and Director, Field HEOR & Scientific Excellence (2023–2025), focused on improving patient access to the BMS portfolio. Gabrielle was also Associate Director, Health Systems Liaison there (2018–2022).
Is this you? Claim your profile and get paid for calls.
Joelle Hallak
LinkedInExperience: Director, Global Health Economics and Outcomes Research, Strategy Lead · AbbVie
$505 per 30-minute call
Joelle Hallak holds Director, Global Health Economics and Outcomes Research, Strategy Lead at AbbVie (since November 2023) after Associate Director, Health Economics and Outcomes Research, Real-World Evidence there (2021–2023), with strategic experience in evidence generation and value demonstration across the asset lifecycle. Joelle was Executive Director, Ophthalmic Clinical Trials and Translational Center at UIC Department of Ophthalmology and Visual Sciences (2015–2020).
Is this you? Claim your profile and get paid for calls.
Kyle Hvidsten
LinkedInExperience: Executive Director, HEOR · Alnylam Pharmaceuticals
$539 per 30-minute call
Kyle Hvidsten, Executive Director, HEOR at Alnylam Pharmaceuticals since January 2026, was Head of Specialty Care Global HEVA and RWE (2020–2025) and Head of Global Health Economics and Value Assessment (HEVA) (2017–2020) at Sanofi, and Head of Global Market Access (2013–2017) and Head of Global Health Economics (2011–2013) at Vertex Pharmaceuticals. Kyle has led teams in pricing strategy, reimbursement negotiations and evidence generation.
Is this you? Claim your profile and get paid for calls.
Xingdi Hu
LinkedInExperience: Director, Health Economics & Outcome Research (HEOR) Cardiovascular · Novartis
$505 per 30-minute call
Director, Health Economics & Outcome Research (HEOR) Cardiovascular at Novartis since August 2021, Xingdi Hu brings experience leading global HEOR and market access and reimbursement strategies for new product launches in US and ex-US markets and HTA submissions. Xingdi was Associate Director, Global Value & Access at Kiniksa Pharmaceuticals (2020–2021) and Senior Manager, Global Health Economics and Outcome Research at Vertex Pharmaceuticals (2018–2020).
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
For global value strategy and HTA submissions, Xingdi Hu, Kyle Hvidsten, Agathe Le Lay and Brooke S. Harrow are the closest fits. Real-world evidence and modeling questions go to Ankur A. Dashputre, Joelle Hallak or Bhavini P. Srivastava; oncology value evidence to Bhavik J. Pandya; and field HEOR teams to Gabrielle Williams.
Questions to take into the conversation
- 01At what stage of development should the first cost-effectiveness model be built, and who should own its assumptions?
- 02When a payer doubts a trial-based value claim, which real-world data source is most persuasive to bring back?
- 03What did a reimbursement submission that failed have in common, and what would you change in the evidence plan?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.